Recently, our laboratory has shown the important role of CD36 in enhancing cellular proliferation and progression of primary CRC and identified upregulation of CD36 as a potential mechanism of resistance to FASN-targeted therapy [15]. The gene discussed is CD36; the disease is colorectal carcinoma.